Latigo Biotherapeutics, Inc.
LTGONasdaqCIK 2056611HealthcareFiscal year ends Dec 31
Reports and events: 7 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0316:32 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-381969 |
| 2026-09-0316:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-381912 |
| 2026-08-1719:06 ET | SCHEDULE 13D | Ownership report, active investor | 0001104659-26-097980 |
| 2026-08-1016:02 ET | 8-K | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-342321 |
| 2026-08-0421:54 ET | S-1/A | Registration statement, amended | 0001193125-26-331205 |
| 2026-08-0306:06 ET | S-1/A | Registration statement, amended | 0001193125-26-329431 |
| 2026-07-1712:33 ET | S-1 | Registration statement | 0001193125-26-307306 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 18:05 ET. Listed shows no prices and gives no investment advice.